Oral feeding effect on COPD patients
Part of Lungs & breathing clinical trials.
This trial tests if a special oral supplement can improve health in patients with COPD. It may help if you have stable heart function and no major heart conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have COPD confirmed by a breathing test
- Your resting heart rate is between 50 and 120 beats per minute
- You have no history of heart failure, chest pain, heart attack, stroke, or severe circulation problems
- You are not allergic to metoprolol or similar drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether sildenafil tablets can improve exercise ability, shortness of breath, and heart-lung function in people with COPD. It also compares against people without COPD to better understand how sildenafil affects breathing tests.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This trial tests a new drug, BBT002, first in healthy volunteers and then in people with chronic obstructive pulmonary disease (COPD) or chronic sinusitis with nasal polyps. It aims to see if the drug is safe and how it works in the body.
This study tests whether a structured care program for COPD can lower how often your symptoms flare up. It may help by improving everyday management and preventing future worsening.
This early trial tests whether inhaled nitric oxide changes how well your lungs exchange gases during exercise in people with COPD, and compares results with healthy volunteers. It may help researchers understand lung blood-flow and breathing differences that could affect symptoms and exercise tolerance.
This trial tests whether a low dose of metoprolol (a beta-blocker) is safe and helpful for people who have both heart failure with reduced pumping ability and COPD. The goal is to see if it can improve heart function without worsening breathing problems.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.